Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Aclaris Therapeutics, Inc. | acrs-20201231xex32d1.htm |
| EX-31.2 - EX-31.2 - Aclaris Therapeutics, Inc. | acrs-20201231xex31d2.htm |
| EX-31.1 - EX-31.1 - Aclaris Therapeutics, Inc. | acrs-20201231xex31d1.htm |
| EX-21.1 - EX-21.1 - Aclaris Therapeutics, Inc. | acrs-20201231xex21d1.htm |
| EX-10.16 - EX-10.16 - Aclaris Therapeutics, Inc. | acrs-20201231xex10d16.htm |
| EX-10.12 - EX-10.12 - Aclaris Therapeutics, Inc. | acrs-20201231xex10d12.htm |
| EX-4.2 - EX-4.2 - Aclaris Therapeutics, Inc. | acrs-20201231xex4d2.htm |
| 10-K - 10-K - Aclaris Therapeutics, Inc. | acrs-20201231x10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-212095) and Form S-8 (Nos. 333-238079, 333-230614, 333-223922, 333-220149, 333-216703, 333-210379 and 333-207434) of Aclaris Therapeutics, Inc. of our report dated February 25, 2021 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Philadelphia, Pennsylvania
February 25, 2021